Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65

NCT00785330 is registered in ClinicalTrials.gov with Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH as lead sponsor.

NCT NCT00785330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00785330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65
Lead sponsor
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
April 30, 2011
Enrollment
84 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma